Oxaliplatin-DNA Adduct Formation in Cancer Patients
Author Information
Author(s): Pieck A C, Drescher A, Wiesmann K G, Messerschmidt J, Weber G, Strumberg D, Hilger R A, Scheulen M E, Jaehde U
Primary Institution: University of Bonn
Hypothesis
This study investigates the kinetics of oxaliplatin-DNA adduct formation in white blood cells of cancer patients in relation to efficacy and neurotoxicity.
Conclusion
The study found that oxaliplatin-DNA adduct levels were significantly higher in patients who responded to treatment compared to nonresponders.
Supporting Evidence
- Oxaliplatin-DNA adduct levels were significantly higher in responders after 24 and 48 hours compared to nonresponders.
- Patients with higher adduct levels experienced more pronounced neurotoxicity, although not significantly different.
- The study highlights the potential of measuring DNA adducts as a pharmacodynamic endpoint in clinical trials.
Takeaway
Doctors studied how a cancer drug called oxaliplatin affects DNA in white blood cells to see if it helps treat cancer and causes side effects.
Methodology
Patients received oxaliplatin as a 2-hour infusion, and DNA adduct levels were measured using adsorptive stripping voltammetry.
Limitations
The study was limited by the small sample size and the variability in individual responses to treatment.
Participant Demographics
{"total_patients":37,"male":26,"female":11,"age_range":"32-80","median_age":59}
Statistical Information
P-Value
0.007
Statistical Significance
p=0.007
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website